Trevi Therapeutics (TRVI) EBITDA (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly EBITDA of -$13.0 million for Q1 2026, down 27.61% year-over-year from -$18.0 million in Q1 2025, and down 27.22% quarter-over-quarter from -$10.2 million in Q4 2025.
Trevi Therapeutics (TRVI) EBITDA (2018 - 2026) Analysis & Trends
Trevi Therapeutics' EBITDA history runs 9 years deep, the most recent figure standing at -$13.0 million for Q1 2026.
- In Q1 2026, EBITDA fell 27.61% year-over-year to -$13.0 million; the TTM figure through Mar 2026 stood at -$50.9 million (down 2.11% YoY), while the FY2025 annual figure was -$49.3 million, up 4.26% from the prior year.
- EBITDA for Q1 2026 stood at -$13.0 million, down from -$10.2 million in the prior quarter.
- The five-year high for EBITDA was -$6.7 million in Q4 2022, with the low at -$14.1 million in Q3 2024.
- The 5-year median for EBITDA is -$10.2 million (2025), against an average of -$10.4 million.
- The sharpest annual moves came in 2022 and 2024: EBITDA climbed 19.53% in 2022, then tumbled 58.54% in 2024.
- Trevi Therapeutics' EBITDA stood at -$6.7 million in 2022, then plunged by 34.19% to -$8.9 million in 2023, then plunged by 37.05% to -$12.2 million in 2024, then rose by 16.52% to -$10.2 million in 2025, then fell by 27.22% to -$13.0 million in 2026.
- Business Quant data shows TRVI's EBITDA at -$13.0 million in Q1 2026, -$10.2 million in Q4 2025, and -$13.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | -17.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.36 Mn |
| Mar 31, 2026 | -13.00 Mn |
| Dec 31, 2025 | -10.22 Mn |
| Sep 30, 2025 | -13.92 Mn |
| Jun 30, 2025 | -13.72 Mn |
| Mar 31, 2025 | -10.19 Mn |
| Dec 31, 2024 | -12.24 Mn |
| Sep 30, 2024 | -14.09 Mn |
| Jun 30, 2024 | -13.29 Mn |
| Mar 31, 2024 | -11.91 Mn |
| Dec 31, 2023 | -8.93 Mn |
| Sep 30, 2023 | -9.05 Mn |
| Jun 30, 2023 | -8.38 Mn |
| Mar 31, 2023 | -7.56 Mn |
| Dec 31, 2022 | -6.66 Mn |
| Sep 30, 2022 | -8.41 Mn |
| Jun 30, 2022 | -7.82 Mn |
| Mar 31, 2022 | -7.03 Mn |
| Dec 31, 2021 | -8.27 Mn |
| Sep 30, 2021 | -6.95 Mn |